Cardiovascular risk assessment of atypical antipsychotic drugs in a zebrafish model

Journal of Applied Toxicology

Volumn 33, Issue 6, 2013, Pages 466-470

  Lee, Sung Hak ^a   Kim, Hong Rye ^a   Han, Rong Xun ^a   Oqani, Reza K ^a   Jin, Dong Il ^a  

^a Chungnam National University   (South Korea)

Author keywords

Atypical antipsychotic drug; Cardiotoxicity; Heart beat rate; LC50; Zebrafish

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING; BODY BUILD; CARDIOTOXICITY; CARDIOVASCULAR RISK; CIRCULATION; CONTROLLED STUDY; DRUG SCREENING; EDEMA; HEART EDEMA; HEART RATE; LARVA; LD 50; LETHALITY; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; TRUNK EDEMA; ZEBRA FISH;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; ENDPOINT DETERMINATION; FEMALE; HEART RATE; HEMODYNAMICS; LARVA; LETHAL DOSE 50; MALE; MOTOR ACTIVITY; RISK ASSESSMENT; ZEBRAFISH;

DANIO RERIO; MAMMALIA;

EID: 84876707193     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1768     Document Type: Article

References (25)

1. Abdelmawla N, Mitchell AJ. 2006. Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanism. Adv. Psychiat. Treat. 12: 35-44.
2. Akande MG, Orn S, Norrgren L. 2010. Evaluation of the toxic effects of clozapine in zebrafish (Danio rerio) embryos with the fish embryo toxicity test. Int. J. Pharm. Biol. Res. 1: 71-75.
3. AstraZeneca. 2010. Product monograph: Seroquel (quetiapine fumarate tablets), AstraZeneca Canada; 34-36.
4. Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S. 2008. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br. J. Pharmacol. 154: 1400-1413.
5. Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, Golder Z, Richards FM, Kimber G, Roach A, Alderton W, Fleming A. 2008. Zebrafish based assays for the assessment of cardiac, visual and gut function - potential safety screens for early drug discovery. J. Pharmacol. Toxicol. Meth. 58: 59-68.
6. Bowman TV, Zon LI. 2010. Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem. Biol. 5: 159-161.
7. Eimon, P.M., Rubinstein, A.L., 2009. The use of in vivo zebrafish assays in drug toxicity screening. Exp. Opin. Drug Metab. Toxicol. 5: 393-401.
8. EMEA. 2010. European public assessment reports: Olanzapine Teva product information, EMEA/H/C/000810-IA/0039; 83-84.
9. Fermion. 2010. Material Safety Data Sheet. Update 2010.3.3.
10. HSDB. n.d. Hazardous Substances Data Bank on TOXNET, US National Library of Medicine, National Institute of Health. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB
11. Koponen H, Alaraisanen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, Savolainen M, Isohanni M. 2008. Schizophrenia and sudden cardiac death: a review. Nord. J. Psychiat. 62: 342-435.
12. McDonagh MS, Peterson K, Carson S, Fu R, Thakurta S. 2010. Drug class review: atypical antipsychotic drugs: final update report. Oregon Health and Science University; 137-140.
13. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. 2003. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107: 1355-1358.
14. Mittelstad SW, Hemenway CL, Craig MP, Hove JR. 2008. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J. Pharmacol. Toxicol. Meth. 57: 100-105.
15. Newcomer JW. 2005. Second-generation (atypical) antipsychotics and metabolic effects a comprehensive literature review. CNS Drugs 19(suppl. 1): 1-93.
16. Novatis. 2010. Clozaril®(clozapine) Prescibing Information. Novatis Pharmaceuticals Corporation, T2010-122.
17. Nutra Specialities. 2008. Material safety data sheets: Rispedione, Section 11. Toxicological information.
18. OECD. 1998. Fish, Short-term Toxicity Test on Embryo and Sac-fry Stages. OECD Guideline for Testing of Chemicals no. 212.
19. Pfizer. 2010. Geodon® (Ziprasidone HCl capsulea). Highlights of prescribing information. Pfizer Inc. LAB-0273-17.
20. Seeman P. 2004. Atypical antipsychotics: mechanism of action. J. Lifelong Learning Psychiat. 2: 48-58.
21. Seibt KJ, Oliveira RL, Rico EP, Dias RD, Bogo MR, Bonan CD. 2009. Typical and atypical antipsychotic alter acetylcholinesterase activity and ache expression in zebrafish (Danio rerio) brain. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 150: 10-15.
22. Ton C, Lin Y, Wilett C. 2006. Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res. (Pt A) 76: 553-567.
23. Westerfield M. 2007. The Zebrafish Book; a Guide for the Laboratory Use of Zebrafish (Danio rerio), 5th edn. University of Oregon Press: Eugene, OR.
24. Zhang C, Wilett C, Fremgen, T, 2003. Zebrafish: an animal model for toxicological studies. Curr. Protocols Toxicol. 1.7.1-1.7.18; doi: 10.1002/0471140856.tx0107s17.
25. Zon L, Peterson R. 2005. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4: 35-44.